Acrivon Therapeutics, Inc. Common Stock (ACRV) — Cash Flow-to-Debt Ratio
Acrivon Therapeutics, Inc. Common Stock (ACRV) has a Cash Flow-to-Debt Ratio of -0.74x as of September 2025, meaning its operating cash flow of $-12.28 Million could theoretically repay -1% of its total liabilities ($16.70 Million) in one year. See Acrivon Therapeutics, Inc. Common Stock (ACRV) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Acrivon Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio (2020–2024)
Historical debt coverage capacity for Acrivon Therapeutics, Inc. Common Stock across 5 annual periods. Also explore how fast is Acrivon Therapeutics, Inc. Common Stock growing its equity to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Acrivon Therapeutics, Inc. Common Stock (2020–2024)
Year-by-year debt coverage analysis for Acrivon Therapeutics, Inc. Common Stock. For market capitalisation and broader financial context, see ACRV stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -3.32x | $-65.67 Million | $19.80 Million | ▼ -32.8% |
| 2023 | -2.50x | $-42.64 Million | $17.07 Million | ▲ +10.8% |
| 2022 | -2.80x | $-30.12 Million | $10.75 Million | ▼ -2512.5% |
| 2021 | -0.11x | $-13.98 Million | $130.40 Million | ▲ +59.5% |
| 2020 | -0.26x | $-2.80 Million | $10.60 Million | — |